A New Meta-Analysis of 2025 Confirmed the Effectiveness of Low-Carbohydrate Diets in Weight Control and Metabolic Syndrome

A recent study from 2025 presented a large-scale meta-analysis dedicated to examining the impact of low-carbohydrate diets on body weight control and markers of metabolic syndrome. The results confirmed that such diets contribute to significant weight loss and improve biochemical indicators, including triglyceride and blood glucose levels.

Low-carbohydrate diets have long been used in medicine to correct alimentary-dependent risk factors, including obesity and related cardiovascular diseases. Previously conducted meta-analyses, including publications from 2018-2019, showed a reduction in glycated hemoglobin HbA1c levels and body weight in patients with diabetes and excess weight who followed very low (<50 g per day) and low (50–130 g per day) carbohydrate diets[1][2].

The modern meta-analysis of 2025 expanded these findings, confirming the positive effect of low-carbohydrate approaches on weight control and metabolic status. In particular, it was found that low-carbohydrate diets contribute to:

• Weight loss due to a reduction in fat tissue;
• Reduction in triglyceride levels and improvement in lipid profile;
• Improvement in glycemic control and reduction in blood glucose levels;
• Positive effects on key indicators of metabolic syndrome.

At the same time, the authors note differences in effectiveness depending on the degree of carbohydrate restriction. Very low-carbohydrate diets (<50 g per day) have a more pronounced effect on reducing fat mass compared to moderately low-carbohydrate diets (about 40% of calories from carbohydrates)[3].

Despite the proven effectiveness, some studies indicate potential risks of long-term adherence to strict low-carbohydrate diets, including increased mortality in certain patient groups, which requires careful clinical monitoring and an individualized approach[4].

Thus, the results of the 2025 meta-analysis confirm the key role of low-carbohydrate diets in the modern treatment of obesity and metabolic syndrome, while emphasizing the importance of personalization and regular medical supervision to minimize risks.